Der Gastroenterologe

, Volume 10, Issue 1, pp 47–55 | Cite as

Tumoren bei chronisch-entzündlichen Darmerkrankungen

CME Zertifizierte Fortbildung
First Online:
  • 283 Downloads

Zusammenfassung

Chronisch-entzündliche Darmerkrankungen, wie Colitis ulcerosa und Morbus Crohn, erhöhen in Abhängigkeit von der Erkrankungsdauer, -lokalisation und -ausdehnung das Risiko, an einem kolorektalen Karzinom zu erkranken. Neben der Möglichkeit einer Chemoprävention mit 5-Aminosalicylsäure-Präparaten stellt in erster Linie die regelmäßige Koloskopie die Grundlage einer bestmöglichen Vorsorgestrategie dieses kolitisassoziierten Karzinoms dar. Zusätzlich zur Weißlichtkoloskopie mit Stufenbiopsien hat sich v. a. die hochauflösende Chromoendoskopie zur Methode der Wahl entwickelt. Bei Nachweis dysplastischer Tumorvorstufen erfolgt das weitere Vorgehen entsprechend der histologischen Differenzierung und dem damit verbundenen Karzinomrisiko. Diese CME-Fortbildung gibt einen Überblick über aktuelle Empfehlungen zur Diagnostik und Therapie des kolitisassoziierten Karzinoms.

Schlüsselwörter

Morbus Crohn Colitis ulcerosa Kolorektales Karzinom Koloskopie Vorsorge 

Tumors in chronic inflammatory bowel disease

Abstract

Inflammatory bowel diseases (e.g., ulcerative colitis and Crohn’s disease) are associated with an increased risk for colorectal cancer depending on the duration, location and extent of disease. Besides the possibility for chemoprevention with 5-aminosalicylates, surveillance colonoscopy represents the most important approach for successful prevention of this colitis-associated cancer. In this regard, white-light endoscopy with random biopsies or high definition chromoendoscopy with targeted biopsies are state-of-the-art techniques for the identification of suspect lesions. Treatment of precursor lesions depends on the histological classification and the associated risk for synchronous or metachronous colorectal cancer. This CME training will provide the reader with an overview of current recommendations for the diagnosis and therapy of colitis-associated cancer.

Keywords

Crohn disease Ulcerative colitis Colorectal cancer Colonoscopy Prevention 
This is a preview of subscription content, log in to check access.

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. J. Waldner und M. F. Neurath geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Morson BC (1966) Cancer in ulcerative colitis. Gut 7:425–426PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526–535PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMedCrossRefGoogle Scholar
  4. 4.
    Canavan C, Abrams KR, Mayberry J (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 23:1097–1104PubMedCrossRefGoogle Scholar
  5. 5.
    Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121:2373–2380PubMedCrossRefGoogle Scholar
  7. 7.
    Waldner MJ, Neurath MF (2012) Potential avenues for immunotherapy of colitis-associated neoplasia. Immunotherapy 4:397–405PubMedCrossRefGoogle Scholar
  8. 8.
    Hussain SP, Amstad P, Raja K et al (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60:3333–3337PubMedGoogle Scholar
  9. 9.
    Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer 3:276–285PubMedCrossRefGoogle Scholar
  10. 10.
    D’Incà R, Cardin R, Benazzato L et al (2004) Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis 10:23–27CrossRefGoogle Scholar
  11. 11.
    He G, Karin M (2011) NF-κB and STAT3 – key players in liver inflammation and cancer. Cell Res 21:159–168PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Feldmann M, Maini RN (2010) Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol 185:791–794PubMedCrossRefGoogle Scholar
  13. 13.
    Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353 (Division of Gastroenterology and UCSF Center for Colitis and Crohn’s Disease, University of California, San Francisco, California 94143, USA)PubMedCrossRefGoogle Scholar
  14. 14.
    Dignass A, Preiss JC, Aust DE et al (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 49:1276–1341PubMedCrossRefGoogle Scholar
  15. 15.
    Van Assche G, Dignass A, Bokemeyer B et al (2013) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 7:1–33CrossRefGoogle Scholar
  16. 16.
    Reifen R, Nissenkorn A, Matas Z, Bujanover Y (2004) 5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis. J Gastroenterol 39:514–519PubMedCrossRefGoogle Scholar
  17. 17.
    Collins PD, Mpofu C, Watson AJ, Rhodes JM (2006) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev CD000279. doi:10.1002/14651858.CD000279.pub3Google Scholar
  18. 18.
    Annese V, Daperno M, Rutter MD et al (2013) European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7:982–1018PubMedCrossRefGoogle Scholar
  19. 19.
    Neurath MF, Kiesslich R (2009) Is chromoendoscopy the new standard for cancer surveillance in patients with ulcerative colitis? Nat Clin Pract Gastroenterol Hepatol 6:134–135PubMedCrossRefGoogle Scholar
  20. 20.
    Thomas T, Abrams KA, Robinson RJ, Mayberry JF (2007) Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 25:657–668PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Medizinische Klinik 1Universitätsklinikum ErlangenErlangenDeutschland

Personalised recommendations